HF
NEUP

HRT Financial’s Neuphoria Therapeutics NEUP Stock Holding History

HRT Financial’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$99K Buy
+22,865
New +$110K ﹤0.01% 3618

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

HRT Financial's NEUP Position: Q2 2026 in Review

HRT Financial opened a new position in Neuphoria Therapeutics (NEUP) in Q2 2026: 22,865 shares worth $99K. The stake represents ﹤0.01% of the portfolio and ranks #3618 among its holdings.

22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • HRT Financial held 22,865 shares of Neuphoria Therapeutics worth $99K as of Q2 2026.
  • Neuphoria Therapeutics was a new HRT Financial position in Q2 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3618 holding.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.